Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD May Be The Culprit
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for the TriLipix/Crestor combination drug is the subject of an FDA "complete response" letter.
You may also be interested in...
All Trilipix Options Available To Advisory Committee
ACCORD-Lipid trial results could lead members to recommend conducting another trial, revising the label, withdrawing the indication or take no action for Trilipix coadministration with a statin.
All Trilipix Options Available To Advisory Committee
ACCORD-Lipid trial results could lead members to recommend conducting another trial, revising the label, withdrawing the indication or take no action for Trilipix coadministration with a statin.
AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.